VIRX
Viracta Therapeutics Inc

12,697
Loading...
Loading...
News
all
press releases
Stocks Set to Open Lower as Investors Trim Risk Amid Year-End Uncertainty
March S&P 500 E-Mini futures (ESH25) are down -0.22%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.20% this morning, adding to Friday’s declines on Wall Street, as market participants reduced positions amid uncertainty heading into year-end.
barchart.com·8mo ago
News Placeholder
More News
News Placeholder
Why Is Cancer-Focused Penny Stock Viracta Therapeutics Trading Higher On Wednesday?
Viracta Therapeutics stock gains after Phase 2 NAVAL-1 trial results for relapsed or refractory EBV+ PTCL cohort. The company plans pipeline reprioritization and a reduction in force. read more...
Benzinga·1y ago
News Placeholder
Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?
Nanatinostat combined with valganciclovir shows promising results in treating relapsed or refractory EBV+ peripheral T-cell lymphoma, demonstrating higher efficacy and tolerability than nanatinostat...
Benzinga·1y ago
News Placeholder
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy...
Globe Newswire·1y ago
News Placeholder
Analysts Are Bullish on These Healthcare Stocks: iTeos Therapeutics (ITOS), Viracta Therapeutics (VIRX)
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on iTeos Therapeutics (ITOS Research Report), Viracta Therapeutics...
TipRanks Financial Blog·1y ago
News Placeholder
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Completed Stage 2 enrollment in the NAVAL-1 trial of Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supporting its speed to market strategy; topline results from...
Globe Newswire·2y ago
News Placeholder
Viracta Therapeutics (NASDAQ:VIRX) Shares Down 8.4%
Shares of Viracta Therapeutics, Inc. (NASDAQ:VIRX Get Free Report) traded down 8.4% during trading on Thursday . The stock traded as low as $0.76 and last traded at $0.82. 190,182 shares were...
Zolmax·2y ago
News Placeholder
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
Accelerated pace of enrollment supports speed to market strategy Topline results from Stage 1 expected to be presented in the second quarter of 2024 followed by Stage 2 data in the third quarter...
Globe Newswire·2y ago
News Placeholder
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...
Globe Newswire·2y ago
News Placeholder
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership team to help structure merged public...
Globe Newswire·2y ago

Latest VIRX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.